The Patient Controlled Injectors Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The market size of patient controlled injectors has experienced significant growth recently. The market, which was worth $4.51 billion in 2024, is projected to reach $5.1 billion in 2025, marking a compound annual growth rate (CAGR) of 13.1%.
The market for patient controlled injectors is predicted to expand to a size of $8.25 billion by 2029, growing at a compound annual growth rate (CAGR) of 12.8%.
Download Your Free Sample of the 2025 Patient Controlled Injectors Market Report and Uncover Key Trends Now!The drivers in the patient controlled injectors market are:
• Expansion and development of home healthcare
• Growth in healthcare infrastructure
• Rising incidence of diabetes
• Increased rate of infectious diseases
• Growing emphasis on personalized medicine
The patient controlled injectors market covered in this report is segmented –
1) By Product: Electronic Wearable Injector, Mechanical Wearable Injector, Infusion Pumps
2) By Application: Cancer Treatment, Auto-Immune Treatment, Blood Disorder Treatment, Other Application
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies
The trends in the patient controlled injectors market are:
• Technological advancements are a key emerging trend in the patient controlled injectors market.
• The integration of artificial intelligence in this field is gaining traction.
• The use of telemedicine and remote monitoring tools is on the rise.
• There is an increasing focus on developing portable and wearable devices and minimally invasive procedures.
The major players in the patient controlled injectors market are:
• Medtronic plc
• Becton Dickinson and Company
• West Pharmaceutical Services
• SCHOTT AG
• Gerresheimer AG
• Phillips-Medisize
• Vetter P
North America was the largest region in the patient controlled injectors market in 2023